Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer - Guideline Learning Activities - Guideline Central

Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer

American Society of Clinical Oncology

Publication Date: January 20, 2026

The Systemic Therapy in Men with Metastatic Castration-Resistant Prostate Cancer guideline, developed by the American Society of Clinical Oncology, provides evidence-based recommendations for the use of systemic therapies in men with metastatic castration-resistant prostate cancer.
14
Questions
30
Minutes Est.
280
Possible Points
Unrated
Difficulty
Objectives
  • Identifying the role of somatic testing in metastatic castration-resistant prostate cancer (mCRPC)
  • Understanding the use of androgen deprivation therapy in mCRPC
  • Recognizing indications for bone-protective agents in mCRPC
  • Learning the role of chemotherapy in mCRPC
  • Identifying features of indolent mCRPC
  • Understanding the use of PSA in mCRPC
Instructions
Answer All QuestionsYou must answer each question to move forward.
Get Instant FeedbackAfter you submit each answer, you'll receive an explanation.
Progress is Saved AutomaticallyYour progress is saved as you go, so you can stop and return to the quiz anytime.
Compare Your ResultsSee how your performance compares with your peers after each answer is submitted.
Earn PointsPoints are awarded for each correct answer.
Members Only FeaturesIf you're a member, you can track your progress and view the quizzes you've completed.
You rely on Guideline Central for transparency

Guideline Central and select third party use “cookies” on this website to enhance the user experience.

This technology helps us gather statistical and analytical information to optimize the relevant content for you.

The user also has the option to opt-out which may have an effect on the browsing experience.